IL-1β conferred doxorubicin resistance to breast cancer cells by elevating the expression of the baculoviral inhibitor of apoptosis repeat-containing 3 (BIRC3), known as an EMT marker [161]. This evidence concerns the gene IL1B and breast carcinoma.